Australia's largest stock trading and investment forum Australia's #1 stock forum

IHL

0.00%

4.1¢ incannex healthcare limited

General discussion, page-16816

First 16816 Last

Share
Profile

Follow
kingkev

27,602 Posts.

1318

29/08/23

18:36

Post #: 69620357
Share

Originally posted by JMiller83: ↑

Understandably there’s been a huge emphasis on disrupting the OSA market with IHL-42X, and it’s certainly a massive opportunity. However, I haven’t seen any commentary from the company on heart disease.

Obstructive sleep apnea has long been associated with increased risk of cardiovascular issues, including heart attack and stroke. I just read an NIH-funded study that was attempting to understand the mechanism involved in heart issues for OSA sufferers. They determined that a reduction in blood oxygen levels is the leading factor.

You might recall that reduced oxygen uptake is a key component of the pathology of OSA. In the most recent OSA trials, Incannex collected data on oxygen desaturation index (ODI). All three doses of IHL-42X reduced ODI compared to baseline to a greater extent than placebo. And for low and medium dose IHL-42X the difference in reduction in ODI relative to baseline compared to placebo was statistically significant (p<0.05). In other words, there was more oxygen in the subject’s blood during sleep while taking IHL-42X.

If the phase 2, 3 pivotal trials are successful then IHL-42X could be a block buster drug for the treatment of OSA. However, I think there’s also the potential opportunity for it to be given to even mild OSA patients as a potential preventative treatment for heart disease. These are significant market opportunities, particularly here in the States.

Thoughts?

Expand

It makes sense but let's wait until Phase 3 done and dusted .............the world is our oyster and at some stage unmet medical needs will be met. A good reason why we should stay focusses on the end result or at least well into 2025 as opposed to thinking the sky has fallen in in 2023 as sp gets played

Any benefit we can muster towards positive impacts in treating heart disease with 42x will be very well received ALL OVER THE WORLD

IHL Price at posting: 8.2¢ Sentiment: Buy Disclosure: Held
4 Upvote

1 Great analysis

Reply

Top Stories

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Brightstar tops votes in 2024 Kalgoorlie Super PITch

Revolutionary inverter technology leads the clean energy charge

From the Floor with Kim Beazley at Diggers and Dealers 2024

RBA keeps rates steady at 4.35%, reflecting expectations